PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2024 Financial and Operational Review Protalix Biotherapeutics, Inc.
Renal & Urology News15h
SGLT2 Inhibitors Might Lower Stone Risk Better Than Other Type 2 Diabetes Drugs
SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...
Rolling Out5h
5 urgent CKM syndrome strategies to manage cardiovascular risks
This syndrome plays a significant role in elevating the risk of developing cardiovascular diseases, which encompass serious ...
Rolling Out5h
5 powerful sound therapy to transform your worst sleep struggles
The journey to optimal sleep is personal and complex. Sound therapy represents just one potential pathway in the broader ...